McGill, and Barbara Powers was formed to accomplish this objective. The survey developed by this subcommittee was reviewed by epidemiologists and other committee members. The final survey incorporated suggestions from these sources. The survey was mailed to all 735 members of the Veterinary Cancer Society on 30 May 2000; 11 were returned because of address errors, and 277 were completed and returned by 1 August 2001. The response rate approached 38%, which was interpreted as a demonstration of strong interest in the project.
The survey started with the following introductory paragraph:
The American College of Veterinary Pathologists has formed an ad hoc committee on oncology to determine ways in which the diagnosis and grading of tumors can be improved to meet the evolving needs of veterinarians who treat animals with cancer. To help us ascertain what veterinary oncologists expect and need from diagnostic pathology services and how important different needs are to patient management, please answer the questions in this short survey and return it to the enclosed address. Your response by 15 July 2001 would be appreciated.
The questions included in the survey and a summary of the responses received are shown in the Appendix. The first question was posed to determine which components of a pathology report were most useful to veterinary oncologists. The respondents rated these components in descending order of importance as follows: 1) surgical margins, 2) diagnosis, 3) grade (if available), 4) histologic description, 5) mitotic index, and 6) pathologist's opinion of prognosis. Surgical margins and diagnosis are the most important parts of the report. Tumor grade is also important. The description is of limited importance to some clinicians. Alternatively, some oncologists expressed the opinion that it should be considered malpractice for a pathologist to send out a report without a microscopic description. Mitotic index as an isolated result is not important to the majority of respondents. Its importance appears to reside in its use as a key factor in grading tumors. The pathologist's prognosis is the least important component for clinicians. Because pathologists rarely have access to full information about the case and are unaware of many factors that affect disease outcome, their ability to assess prognosis is somewhat limited.
In response to the second question, respondents rated the factors that determined their choice of pathology diagnostic providers as follows: 1) reliability of results, 2) short turnaround time, 3) easy access to the pathologist for consultation, 4) rapport with pathologist, 5) convenience of service, and 6) cost of the service. As expected, most respondents indicated that confidence in the results produced by the pathology service is the most critical factor in determining where they chose to send their samples. They want a service that produces reliable diagnoses and they want them reported quickly. Somewhat less important, but still rated highly by nearly all the respondents, are the related factors of ready access to and comfortable working relationship with the pathologist. It is reasonable to infer that an effective, trusting, collaborative relationship between clinical oncologist and pathologist becomes extremely important in cases where the morphologic diagnosis is inconclusive. Cost and convenience of the diagnostic service appear to have little or no influence on the oncologists' choice of pathology service.
The third, fourth, and fifth questions were intended to explore the perceptions of clinicians regarding the value of special staining procedures in the morphologic diagnosis and grading of tumors. The pattern of responses to Question 3 implies that many clinicians believe that pathologists can adequately identify and grade most tumors using only the characteristics visible in HE-stained sections. This perception of pathologists' skills is flattering but rather unrealistic. There are neoplastic diseases with morphologic similarities, for example lymphomas, myeloid leukemias, and other round cell tumors, for which additional staining or labeling procedures are necessary for definitive diagnosis. Soft-tissue sarcomas compose another category of tumors for which special procedures may be needed to obtain a specific diagnosis. For some neoplasms, the accuracy of predicting prognosis or response to therapeutic modalities is significantly increased by results of special procedures. On the basis of the responses to this question, the committee recommends that we consider developing educational materials or programs to increase clinicians' awareness of the limitations of strictly morphologic diagnosis and the real and potential usefulness of special procedures. The responses to Question 4 indicate a gratifying level of confidence in the recommendations of pathologists for additional studies. Most clinicians depend on their pathologist for guidance in the area of special procedures and readily agree to those that their pathologist thinks are necessary for making a clinically useful diagnosis. These responses further emphasize the importance of the clinician-pathologist relationship. Question 5 was confusing to some respondents as to whether this was a price per stain or a total cost of the procedures ordered. The question was meant to be total cost, and most respondents understood that interpretation. It appears that $50-$125 is a range that most clinical oncologists view as an acceptable cost given the value of the results. This range may be valuable as a guide for pricing. For those instances when the expense of testing to obtain an optimal clinical diagnosis exceeds this range, clients are more likely to agree to the cost if the oncologist can provide clear and compelling reasons for performing the procedure. Most assuredly, good communications between the pathologist and clinician will be beneficial in obtaining client approval for additional testing.
On the basis of the responses to Question 6, clinical oncologists generally agree with pathologists that the neoplastic diseases in this list deserve improved grading schemes. More than 85% of the respondents agreed or strongly agreed that these neoplasms, with the exception of nonlymphoid leukemias, should be the focus of consideration. The responses in the ''strongly agree'' column indicated that mast-cell tumors are of most importance to the oncologists, but soft-tissue sarcomas and mammary tumors are of almost as much interest. The respondents expressed somewhat less interest in grading systems for lymphoid, nonlymphoid, and histiocytic neoplasia, but even so, at least 73% of the respondents agreed with these nominees for study. If we had asked a different question for these entities (for instance, ''Would it be helpful to develop classification systems using morphologic, immunologic, and cytochemical characteristics that would better predict biologic behavior and response to therapy?''), the oncologists might have been in stronger agreement. However, these responses indicate sufficient interest in all these categories to warrant further study by the committee.
The committee included Question 7 to learn if oncologists felt that other tumors required grading. The most frequently mentioned tumors were melanomas, squamous-cell carcinomas, and osteosarcomas. In light of these responses, it appears that a group of oncologists is of the opinion that consistent grading systems for these tumors should be developed. This presents opportunities for future interactions between oncologists and veterinary pathologists.
The open-ended Question 8 was placed in the survey to solicit any additional information that the re-spondents wished to share. The subcommittee did not expect that a strong effort would be undertaken by respondents to provide information in this space. Somewhat surprisingly, half of the surveys had responses to this question. The most important and commonly expressed thoughts are summarized as follows:
1. Many respondents endorsed our project. 2. Several comments reiterated that the grading system for mast-cell tumors needs to be reevaluated and refined, apparently because the Grade II category is too broad. 3. There were many comments on ''margin determination.'' These included requests for assistance on how to submit lesions to pathology laboratories so that margins could be evaluated appropriately. Some respondents wanted to know the best method of marking margins and whether the ACVP could produce a guide for standard procedures. There were several suggestions by oncologists that pathologists should examine and cut-in all tissues and not let technicians trim tissues. Several comments relating to complete excision stated that statements on lymphatic and/or vascular invasion might be more important than surgical margin determination. 4. Many respondents wanted pathologists to include therapeutic recommendations in their reports. Just as many, or more, wanted veterinary pathologists to refrain from making therapeutic recommendations (except for excision). Most of the respondents wanted pathologists to recommend that veterinarians consult oncologists for recommendations about therapy. 5. A monthly newsletter publishing new therapy and/ or sources (locations) for specific therapy was suggested. It is the committee's opinion that this project would be more appropriately undertaken by the Veterinary Cancer Society than the ACVP. 6. Several respondents asked for information about how to determine the sensitivity of tumor cells to cancer therapeutic products. 7. There were some complaints that large veterinary pathology practices were pushing samples through too fast; thus, clinicians were concerned about loss of accuracy and reliability. It was noted that rereading slides or cases sometimes resulted in altered diagnoses. There was a mention of licensing veterinary pathology laboratories. 8. Some respondents predicted that tumor diagnosis in the future would not require histopathology and that molecular diagnostic tools would be used to determine treatment plan and prognosis. Associated with this prediction was a suggestion that the ACVP should be in the forefront of research in this area. In contrast, it was commented that as few ancillary tests as possible should be used to make a diagnosis. 9. One respondent indicated the need for a ''politically correct'' means of asking for a second opinion, implying that asking for a second opinion was discouraged because it ''doesn't look good.'' This situation appears to vary depending upon specific institutional settings. 10. A variety of technical improvements were recommended, including the following: ready access to AGNOR staining; ready, rapid, and affordable access to immuno/cytochemical procedures; frozen section examination; readily available, rapid, and affordable access to flow cytometry and other methods to identify other round cell neoplasms such as lymphoid tumors and histiocytic tumors; and chromosome translocation studies or testing. On the basis of this survey, the committee has reached several conclusions. First, there is a strong consensus that oncologists want to work together with veterinary pathologists to provide reliable diagnoses of neoplasia. Second, most oncologists want access to their pathologist to discuss the relationship of the diagnosis to the clinical and therapeutic aspects of the case. Third, there is definitely a need to educate veterinarians treating cancer with respect to 1) types of diagnostic testing available and 2) how to submit samples, particularly for surgical margin determination. There appears to be strong support for the ACVP to provide leadership in these areas. It is important for us, as progressive veterinary pathologists, to be open to changes and improvements that make the diagnosis of neoplasia in animals even more consistent and accurate.
